Latest Holden News
NET SPORE
Monday, April 13, 2026
UI Health Care receives Specialized Program of Research Excellence funding for neuroendocrine tumors.
Kenny recognized with several awards for melanoma research
Thursday, April 2, 2026
Colin Kenny, PhD, has been recognized with multiple awards, but he’s quick to shift the focus to his students. At a recent conference, members of his lab presented research examining how melanoma develops and spreads — work that not only advances the field but also earned awards for each presenter.
Howard Lab breaks through DIPG’s resistance
Wednesday, January 28, 2026
Scientists uncover enzyme that shatters chromosomes, reshapes cancer genomes
Friday, January 9, 2026
Lead study author Ksenia Krupina will join UI Health Care in 2026 to continue her research.
Chemist’s lifelong research comes full circle in his own treatment
Tuesday, January 6, 2026
Garry Buettner, a scientist who spent decades researching the cancer-fighting potential of intravenous vitamin C, became a patient himself, and benefited from the very treatment he helped pioneer—demonstrating both the personal and scientific impact of his work.
PhD student’s research advances treatments for uterine cancer
Monday, December 8, 2025
Katie Colling was named winner of the 2025 3MT competition.
Innovative device could transform patient experience for intensive bladder cancer therapy
Tuesday, December 2, 2025
Why there’s hope for cancer in Iowa
Tuesday, November 25, 2025
These opinions from Mark Burkard, MD, PhD, Mary Charlton, PhD, and Bradley Hiatt, DO, were originally published Nov. 22, 2025, in the Des Moines Register.
UI Health Care awarded grant for AI-enhanced clinical research project aimed at improving advanced prostate cancer care
Friday, November 7, 2025
Clinicians at the University of Iowa were recently awarded a competitive grant for a multi-faceted quality improvement project using artificial intelligence (AI) to improve advanced prostate cancer care.
How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies?
Wednesday, November 5, 2025
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Pagination